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Alternative splicingThe PLP1 gene encodes two protein isoforms (PLP and DM20) which represent the predominant protein
portion in myelin of the central nervous system. The two products are generated from the same primary
transcript by alternative splicing. Defects of the PLP1 gene cause Pelizaeus–Merzbacher disease (PMD) or X-
linked spastic paraplegia type 2 (SPG2). Duplication of the PLP1 gene is the most frequent gene defect,
usually responsible for the classic form of PMD. To investigate the effects of PLP1 gene over dosage on gene
expression, we analysed the PLP/DM20 expression proﬁle in ﬁbroblasts from three PMD patients with a
PLP1 gene duplication. Gene expression was evaluated by real-time PCR using two different PLP1 amplicons
and two different reference genes (GAPDH and GUSB). Fibroblasts from the three patients showed a 4–5 fold
increase of PLP1 gene expression compared to ﬁbroblasts from three normal controls. The contribution of
the two alternatively spliced transcript isoforms (PLP and DM20) to the whole PLP1 gene expression was
investigated using a DM20-speciﬁc amplicon. The three patients showed a decrease of the DM20/
(DM20+PLP) ratio in comparison to the three normal controls, suggesting a prominent contribution of the
PLP transcript to the PLP1 gene overexpression detected in the patients. Therefore, PLP1 gene duplication
seems to result both in overexpression and in a shift of the PLP/DM20 splicing balance in direction of the PLP
isoform.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionThe proteolipid protein 1 gene (PLP1; GeneID: 5354) is a myelin-
related gene encoding two highly hydrophobic transmembrane
proteins, PLP and DM20, which are the major protein components in
myelin of the central nervous system [1,2]. The two products are
generated from the same primary transcript by two competing 5′
donor sites in exon 3 to the same 3′ acceptor site in exon 4 [3]. As a
result of the alternative splicing, DM20 lacks 35 amino acids in
comparison to PLP which is 276 amino acids long.
Defect of the PLP1 gene can cause a broad spectrum of clinical
phenotypes ranging from the connatal form of Pelizaeus–Merzbacher
disease (PMD) to the pure form of X-linked spastic paraplegia type 2
(SPG2). Symptoms vary from a severe picture evident at birth, with
spasticity, stridor and nystagmus, to a relatively mild condition of
paraparesis with no cognitive impairment. PMD/SPG2 is inherited as
an X-linked trait, the PLP1 gene lying in Xq22.
The role of the PLP/DM20 proteins has not been fully elucidated. In
knock-out mice lacking the Plp1 gene myelination occurs, although
myelin shows a reduced physical stability [4]. Moreover, axonal
degeneration and impaired axonal transport have been observed [5].+39 010 383983.
.it (M. Filocamo).
ll rights reserved.Therefore, PLP/DM20 seem to have a function in the stabilization of
themyelin sheaths, a neuroprotective function of CNSmyelin [6] and a
role in axonal transport [7].
Pointmutations of the PLP1 gene are responsible for 20%of the PMD/
SPG2 cases causing a wide range of clinical phenotypes. Rare total
deletions of the PLP1 gene have been reported to cause a mild form of
PMD/SPG2, with moderate spastic paraplegia and mild cognitive delay.
Duplication of a genomic fragment containing the PLP1 gene is themost
frequent gene defect, accounting for 60–70% of PMD cases [2]. Patients
carrying thePLP1 geneduplication usually show the classic formof PMD,
with onset in the ﬁrst year of life, characterized by nystagmus, mental
retardation and spasticity. The presence of more than two PLP1 gene
copies has been reported in a small number of patients showing a severe
form of PMD [8]. Among patients carrying a PLP1 gene duplication,
although usually displaying the classic form of the disease, the degree of
clinical severity can vary. This variability does not correlate to the
variability of the PLP1 gene duplication extension [9].
Increased PLP1 gene dosage is presumed to cause overexpression.
However, this has not been experimentally conﬁrmed in human
patients [1]. Conversely, studies on transgenic mice with additional
copies of the Plp1 gene have shown that the severity of the disease is
proportional to gene dosage and overexpression [10–12].
Expression of the PLP1 gene is mainly detected in oligodendro-
cytes, which are the myelinating cells in the central nervous system.
Table 1
Amplicons used for PLP1 gene dosage determination and expression analysis.
Denomination Gene Sequence
Gene dosage determination
Amplicon PLP1gen PLP1 AGTCAGGCAGATCTTTGGCGACTACAAGACCACCATCTG
CGGCAAGGGCCTGAGCGCAACGGTAACAGGGGGCCAG
AAGGGGAGGGGTTCCAGAGGCCAACATCAAGCTCATTC
TTTGGAGCGGGTGTGTC
Amplicon 830gen PLP1 GAGAGCCAAGGAACTTCTCCCCTAGAATCTCTTCCAGCC
TTCTTGAATCAAACTCACACCCTTTCAACCAGGAGGGGTT
CTGAAATGGAGAGCTTTTGGCT
Amplicon 459gen PLP1 TCACATAACAGAATGCACCAGTCATCAGCTATTCAGTTG
GTAAGCTTCCAGGAAAAAGGACAGGCAGAAAGAGTTT
GAGACCTGAATAGCTCCCAGA TTTC
Amplicon GAPgen GAPDH GGGCTCTCCAGAACATCATCCCTGCCTCTACTGGCGCTG
CCAAGGCTGTGGGCAAGGTCATCCCTGAGCTGAACGGG
AAGCTCACTGGCATGGCCTTCCGTGTCCCCACTGCCAAC
GTGTCAGTGGTGGAC
Gene expression analysis
Amplicon GAD GAPDH GAAGGTGAAGGTCGGAGTCAACGGATTTGGTCGTATTG
GGCGCCTGGTCACCAGGGCTGCTTTTAACTCTGGTAAAG
TGGATATTGTTGCCATCAATGACCCCTTCATTGACCTCAA
CTACATGGTTTACATGTTCCAATATGATTCCACCCATGGC
AAATTCCATGGCACCGTCAAGGCTGAGAACGGGAAGC
TTGTCATCAATGGAAATCCCATCACCATCTTC
Amplicon SB GUSB TAAGGTGCCAGGTGTCAGCCTCTGGTGGCCGTACCTGA
TGCACGAACGCCCTGCCTATCTGTATTCATTGGAGGT
GCAGCTGACTGCACAGACGTCACTGG
Amplicon portions corresponding to primers and probes are underlined. Amplicons
GAD and SB were used as reference for the PLP/DM20 expression studies; PLP/DM20-
related amplicons are reported in Fig. 1.
549S. Regis et al. / Biochimica et Biophysica Acta 1792 (2009) 548–554DM20 is the predominant isoform at embryonic stages, but adult
myelin oligodendrocytes prevalently express PLP rather than DM20
transcripts [13,14]. PLP/DM20 expression in Schwann cells, the
myelinating cell in the peripheral nervous system, is much lower
than that of oligodendrocytes. These cells predominantly express the
DM20 isoform. PLP/DM20 expression has been detected in several
non-myelinating cells. In these cells a prevalence of the DM20 form
has been observed [1]. Cultured ﬁbroblasts express at low levels the
PLP1 gene, producing only a small amount of PLP transcript [15]. We
used cultured ﬁbroblasts obtained from skin biopsies of three PMD
patients carrying a PLP1 gene duplication to analyse their PLP/DM20
expression proﬁle in comparison to that of ﬁbroblasts from normal
controls grown under the same culture conditions. As expected, an
evident overexpression of the PLP1 gene was detected in patients with
duplication of the PLP1 gene. Besides overexpression, a shift of the
PLP/DM20 balance towards the PLP isoform was observed in patients
with duplication compared to normal controls.
2. Materials and methods
2.1. Fibroblast cell lines
Fibroblasts from three PMD male patients and from three male
normal controls were obtained from the “Cell Line and DNA Bank from
Patients affected by Genetic Diseases” collection (http://www.gaslini.
org/labdppm.htm). Patients were classiﬁed as PMD form 3, according
to the PMD score based on the level of the best motor performance
[16].
2.2. DNA, RNA extraction and ﬁrst-strand cDNA synthesis
Genomic DNAwas extracted using the QIAamp DNA Blood Mini kit
(Qiagen, Valencia, CA, USA). Total RNAwas extracted using the RNeasy
Mini Kit (Qiagen). First-strand cDNA synthesis was performed using
the SuperScript III First-Strand Synthesis System for RT-PCR (Invitro-
gen, Carlsbad, CA, USA) according to the manufacturer's protocols.
Priming was performed using simultaneously oligodT (1.25 μM) and
random hexamers (1.25 ng for each reaction). Each ﬁrst-strand cDNA
was obtained using 1 μg of total RNA in a volume of 20 μl.
2.3. Real-time PCR procedure
Ampliﬁcations by real-time PCR were performed from genomic
DNA and from ﬁrst-strand cDNA of patients and controls to determine
the PLP1 gene dosage and to analyse the PLP/DM20 expression proﬁle,
respectively. Amplicons composed of two primers and a TaqMan
probe were designed for the real-time PCR runs using the Primer
Express 1.5 software (Applied Biosystems, Foster City, CA, USA)
according to the previously reported requirements [17]. The real-time
PCR experiments were performed using the Applied Biosystems 7500
Real-Time PCR System and the TaqMan chemistry as previously
described [17]. The standard curve method with ampliﬁcation of the
target and reference sequences in separate tubes was used (User
Bullettin #2. Relative quantitation of gene expression. www.applied-
biosystems.com/). Samples were always run in quadruplicate.
Standards were run in duplicate. All the used TaqMan probes were
labelled with FAM as the reporter ﬂuorophore at their 5′-end andwith
TAMRA as the quencher at their 3′-end. Primers and probes were
purchased by TIB Molbiol (Genoa, Italy).
2.4. PLP1 gene dosage determination
DNA samples of the patients were tested by real-time PCR for PLP1
gene dosage using amplicon PLP1gen, located in exon 3 of the PLP1
gene, and amplicon GAPgen, located in exon 7 of the glyceraldehyde-
3-phosphate dehydrogenase gene (GAPDH), used as reference [17]. Toexclude incomplete PLP1 gene duplications, the copy number of two
ﬂanking amplicons was also tested: amplicon 830gen, located in
intron 1 of the PLP1 gene, and amplicon 459gen, located in the
untranslated portion of exon 7 (Table 1).
2.5. PLP1 gene expression analysis
Patients' and controls' cDNAs were used for PLP1 gene expression
analysis performed by real-time PCR. Combined PLP/DM20 and
selective DM20 expression were evaluated using speciﬁcally designed
amplicons. For the combined ampliﬁcation of the PLP and DM20
cDNAs, amplicons 151 and PL20, lying in a region common to the two
isoform, were designed. Amplicon D2 was designed to selectively
amplify the DM20 cDNA, avoiding the simultaneous ampliﬁcation of
the PLP cDNA. This selectivity was obtained thanks to the reverse
primer of the amplicon, lying across the splicing boundaries of the
DM20 isoform (Fig. 1). Amplicons GAD and SB (Table 1) were used for
the ampliﬁcation of the GAPDH gene and the beta-glucuronidase gene
(GUSB) cDNAs, respectively. Both GAPDH and GUSB genes were used
as reference genes. Sequence of primers and probe of the GAD
amplicon was obtained by User Bullettin #2 by Applied Biosystems.
Total PLP1 gene expression was at ﬁrst determined after normal-
ization to the GAPDH gene expression using amplicon 151 as target
and amplicon GAD as reference. Subsequently, gene expression was
determined after normalization to the GUSB gene expression using
amplicons PL20 as target and amplicon SB as reference.
Expression of the DM20 transcript normalized to the GUSB gene
expression was evaluated using amplicon D2 as target and amplicon
SB as reference.
Expression of the DM20 transcript normalized to the total PLP1
gene expression was determined using amplicon D2 as target and
amplicon PL20 as reference.
In all the above mentioned experiments, standard wells contained
the equivalent of the cDNA obtained from 50, 20, 10, 5, 2, 1, 0.5 ng of
total RNA extracted from a normal male. Each patient and control well
contained the equivalent of the cDNA obtained from 10 ng of total
RNA.
Fig.1. PLP/DM20-related amplicons used for the gene expression analysis. Amplicons PL20 and 151 (on the right side of the diagram) ampliﬁed simultaneously PLP and DM20 cDNAs.
Amplicon D2 (on the left side of the diagram) ampliﬁed selectively DM20 cDNA but not PLP cDNA. The portions of the amplicons corresponding to primers and probes are underlined.
DM20 and PLP cDNAs are schematically represented in the middle part of the diagram. Green bar (PLP cDNA) represents the speciﬁc genomic region of 105 nucleotides of the PLP
isoform. Blue and red bars (PLP and DM20 cDNAs) represent the cDNA regions shared by the two isoforms. Sequences at the blue–red boundary (complementary to the reverse
primer of amplicon D2) and blue–green/green–red boundaries (not-complementary to the reverse primer of amplicon D2) are reported. Red arrows indicate the location of forward
and reverse primers of amplicon PL20 (located at cDNA exon 4 and 5, respectively); blue arrows indicate the location of forward and reverse primers of amplicon 151 (located at cDNA
exon 5 and exons 6–7, respectively).
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expression was also evaluated, again with amplicons D2 and PL20, by
using as standard a plasmid containing the DM20 cDNA. This
experimental proﬁle allowed the determination of the DM20/
(DM20+PLP) ratio, that is the fraction of DM20 on the total
PLP+DM20 amount, in patients and controls. Standard wells
contained 100×10−8, 50×10−8, 25×10−8, 10×10−8, 5×10−8,
2.5×10−8 and 1×10−8 ng/μl of the DM20 cDNA plasmid. This
experimental system was at ﬁrst validated using three kinds of
samples, containing respectively the DM20 cDNA plasmid, a PLP cDNA
plasmid and a mix of the two plasmids. Each sample well contained
10×10−8 ng/μl of plasmid DNA. Subsequently, patient and control
samples were analysed, using in each well the cDNA obtained from
10 ng of total RNA.
To avoid any bias due to between-experiment variation, each
experiment included simultaneously all the analysed patients and
controls.
2.6. Preparation of the PLP and DM20 cDNA containing plasmids
In order to amplify the entire open reading frame of the PLP1 gene,
an endpoint RT-PCR using primers PLPF: 5′-AGACCGAAGAAG-
GAGGCTGGAGAGACCAGG-3′ and PLP1R: 5′-GAGTTAAGATGGGAG-
ACGCAGCATTGTAGG-3′ was performed using ﬁrst-strand cDNA
obtained from a normal control. RT-PCR product was cloned in
pCR2.1 (Invitrogen). Plasmids containing the PLP and DM20 cDNAsTable 2
PLP1 gene dosage determination.
Amplicon (genomic localization) P1 P2 P3 DC MC
830gen (intron 1) 2.0 2.0 2.0 2.1 0.9
PLP1gen (exon 3) 1.9 2.0 2.1 2.1 1.0
459gen (exon 7 UTR) 2.2 2.0 2.2 2.0 0.9
P1, P2, P3: the three PMD patients; DC: male patient carrying the PLP1 gene duplication;
MC: normal male.were selected and subsequently sequenced to exclude the presence of
undesired mutations.
2.7. Analysis of selectivity of the PLP/DM20-related amplicons
To test the selective ampliﬁcation of the PLP and/or DM20 cDNAs
by the PLP1-related amplicons 151, PL20 and D2, endpoint PCRFig. 2. Endpoint PCR reactions performed using forward and reverse primers of
amplicons 151, D2 and PL20. Plasmids containing the PLP cDNA (P), the DM20 cDNA
(D), or a mixture of them (B) were used as templates. C=ampliﬁcation without DNA.
M=molecular weight marker Φx DNA Hae III digested.
Fig. 3. Combined PLP/DM20 expression normalized to the GAPDH and GUSB gene expression. Histogram data (top-half of the ﬁgure) derived from subset data of the related tables
(bottom-half of the ﬁgure) report the results of the real-time PCR experiments performed using amplicon 151 as target (Tamp) and amplicon GAD as reference (Ramp) (A) or
amplicon PL20 as target and amplicon SB as reference (B). The repeated experiments (Exp 1, 2, 3) showed that the PLP1 gene expression in patients (P1, P2, P3) largely exceeded that
in normal controls (C1, C2, C3).
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were performed using as template plasmids containing the PLP cDNA,
the DM20 cDNA, or both.3. Results
3.1. PLP1 gene dosage determination
DNA samples from PMD male patients, of whom a ﬁbroblast cell
line was available, were tested for the presence of the PLP1 gene
duplication according to the real-time PCR-based procedure by Regis
et al. [17], in which the copy number of a portion of PLP1 gene exon
3, covered by amplicon PLP1gen, is determined. As reported in Table
2, three patients (P1, P2 and P3) were found to carry two PLP1 gene
copies showing ratios proximal to the expected value 2 and to the
ratio obtained for the positive control carrying the duplication (DC).
To exclude a partial gene duplication, the copy number of two
ﬂanking regions was also tested with amplicon 830, located in
intron 1 of the PLP1 gene, and amplicon 459, located in the
untranslated portion of exon 7 (Table 1). Experimental ﬁndings
conﬁrmed a good uniformity of the data across the entire gene in
each of the three patients (Table 2).Fig. 4. Selective DM20 expression normalized to the GUSB gene expression. Histogram
data derived from subset data of the related table report the results of the real-time PCR
experiments performed using amplicon D2 as target (Tamp) and amplicon SB as
reference (Ramp).Mean values of the triplicate replicas showed that the patients (P1, P2,
P3) had a 2-fold increase in DM20 expression compared to normal controls (C1, C2, C3).3.2. Selectivity of the PLP/DM20 amplicons
Three PLP/DM20-related amplicons, each composed of a
forward, a reverse primer and a TaqMan probe, were designed.
Amplicons 151 and PL20 matched both the PLP and DM20 cDNAs.
Amplicon D2 was designed to amplify selectively the DM20 cDNA
and not the PLP cDNA (Fig. 1). To verify the selectivity of each PLP/
DM20-related amplicon, primers were tested by endpoint PCR
using as template plasmids containing the PLP or DM20 cDNAs, or
a mixture of the two plasmids. As expected, a PCR product was
obtained in the presence of either PLP or DM20 cDNA using
primers of amplicons 151 and PL20, a PCR product was obtained
only in the presence of the DM20 cDNA using primers of amplicon
D2 (Fig. 2).3.3. Combined PLP/DM20 expression normalized to the GAPDH and
GUSB expression
Once the selectivity of each PLP1-related amplicon was estab-
lished, two amplicons from two different genes chosen as reference
were designed: amplicon GAD, from the GAPDH gene, and amplicon
SB, from the GUSB gene (Table 1). We used amplicon 151 as target and
amplicon GAD as reference to quantify the whole PLP1 gene
expression normalized to the GAPDH gene expression in ﬁbroblasts
from patients and normal controls. The three repeated experiments
revealed a certain variability of the PLP1 gene expression among the
normal controls as well as among the patients. However, PLP1 gene
Fig. 5. Selective DM20 expression normalized to the whole (PLP+DM20) expression.
Histogram and the related tabular data show results of the real-time PCR experiments
performed using amplicon D2 as target (Tamp) and amplicon PL20 (Ramp) as reference.
Mean values of the triplicate replicas from patients (P1, P2, P3) showed a decrease of the
DM20/(DM20+PLP) ratio compared to normal controls (C1, C2, C3).
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Considering the mean values, patients showed more than a 4-fold
increase in gene expression compared to normal controls (Fig. 3A).
To verify these results, excluding undesired error possibly
introduced by the used reference gene or amplicons, we quantiﬁed
the whole PLP1 gene expression normalized to the GUSB gene
expression using PL20 and SB as target and reference amplicon,
respectively. Results of the triplicate replicas were in line with
previous data. Variability among controls and patients was con-
ﬁrmed. Considering again the mean values, patients had more than
a 5-fold increase in gene expression compared to normal controls
(Fig. 3B).3.4. Selective DM20 expression normalized to the GUSB expression
After conﬁrming the PLP1 gene overexpression of the patients with
duplication, we focused on the contribution of PLP and DM20
transcripts to the observed overexpression. Hence, we used amplicon
D2 as target and amplicon SB as reference in order to evaluate the
DM20 expression normalized to the GUSB expression in ﬁbroblasts
from patients and normal controls. Mean values of the triplicate
replicas showed that the patients had a 2-fold increase in DM20
expression compared to normal controls (Fig. 4).Table 3
Veriﬁcation of the real-time PCR proﬁle for the estimation of the DM20/(DM20+PLP)
ratio.
Tamp/Ramp Plasmids containing speciﬁc isoform
D2/PL20⁎ DM20 cDNA DM20 cDNA+PLP cDNA PLP cDNA
Exp 1 1.0 0.5 0
Exp 2 0.9 0.5 0
Exp 3 0.8 0.4 0
Mean 0.9 0.5 0
Expected values 1.0 0.5 0
Tamp=target amplicon; Ramp=reference amplicon; ⁎ this symbol marks the use of a
speciﬁc plasmid DNA as standard (in place of the previously used cDNA from a normal
male). Means of the three replicas and the expected values are in bold.3.5. Selective DM20 expression normalized to the whole
PLP/DM20 expression
To conﬁrm the indication of a limited contribution of the DM20
transcript to the PLP1 gene overexpression, we evaluated the DM20
expression normalized to the whole PLP1 gene expression using
amplicons D2 as target and PL20 as reference. We found that ﬁbroblasts
from patients showed a decrease of the DM20/(DM20+PLP) ratio
compared to normal controls, indicating a shift in the balance between
the PLP and DM20 transcripts (Fig. 5).
3.6. Determination of the DM20/(DM20+PLP) ratio in patients and
controls
To quantify the fraction of DM20 present in normal controls and
in patients with duplication, we used the same D2 and PL20
amplicons previously employed, but the standard curves were
generated using a plasmid containing the DM20 cDNA instead of a
cDNA from a normal control. Using this experimental proﬁle the
expected ratio directly corresponded to the DM20/(DM20+PLP)
ratio. In detail, expected ratios of 1, 0.5, 0 corresponded respectively
to a 100%, 50%, 0% content of DM20 in the total DM20+PLP amount.
To validate this experimental proﬁle we performed three real-time
PCR runs using three kind of samples, containing the DM20 cDNA
plasmid, an equal amount of the DM20 and PLP cDNAs plasmids, or
the PLP cDNA plasmid, respectively. As shown in Table 3, the
concordance between expected and obtained results was evident.
Subsequently, the same experimental proﬁle was used to test cDNAs
from patients and normal controls. Patients showed a mean DM20/
(DM20+PLP) ratio of 0.7, corresponding to a DM20 content in the
total DM20+PLP amount of about the 70%, while normal controls
showed a mean DM20/(DM20+PLP) ratio of 1.0, corresponding to a
DM20 content near to the 100% (Fig. 6).
To conﬁrm data obtained using the DM20-speciﬁc amplicon, we
evaluated the PLP expression normalized to the whole PLP1 gene
expression using a PLP-speciﬁc amplicon named P2 as target and the
PL20 amplicon as reference. We found that ﬁbroblasts from patients
showed an increase of the PLP/(DM20+PLP) ratio compared to
normal controls (data not shown), thus conﬁrming the decrease of theFig. 6. Determination of the DM20/(DM20+PLP) ratio in patients and controls.
Experiments were carried out using amplicons D2 and PL20. The asterisk (D2/PL20⁎)
marks that, differently from previous experiments, the standard curves were generated
using a plasmid containing the DM20 cDNA, instead of a cDNA from a normal control.
Histogram and related tabular data show a mean DM20/(DM20+PLP) ratio of 0.7 and
1.0 for patients and controls, respectively.
553S. Regis et al. / Biochimica et Biophysica Acta 1792 (2009) 548–554DM20/(DM20+PLP) ratio detected using the DM20-speciﬁc
amplicon.4. Discussion
Duplication of the PLP1 gene is the most frequent gene defect
responsible for PMD. Although it is likely that the increased gene
dosage causes overexpression of the gene, up to now, however, it has
not been experimentally conﬁrmed in patients with duplication [1].
Moreover, no data exists concerning the relative frequency of the PLP
and DM20 transcripts in patients carrying the duplication compared
to normal controls.
To investigate on these issues we used ﬁbroblast cells. These cells
are easily obtained from patients and exhibit an acceptable level of
PLP1 gene expression to perform quantitative determinations.
Recently, ﬁbroblasts have been used to study PLP1 splicing abnorm-
alities [18]. However, it must be underlined that ﬁbroblasts do not
have a role in the pathogenesis of PMD. Their PLP1 expression is
considerably lower than that of oligodendrocytes. Moreover, unlike
oligodendrocytes, ﬁbroblasts show a predominant expression of the
DM20 isoform. Nevertheless, ﬁbroblasts can be considered a simple
cellular model in which the consequences of an altered PLP1 gene
dosage can be ascribed to basic mechanisms of regulation of PLP1 gene
expression.
Preliminarily to the expression analysis, copy number of the PLP1
gene in the selected patients was determined in three different
portions of the gene to exclude incomplete gene duplications.
We used real-time PCR for the PLP1 gene expression study, due to
the sensitivity of this technique in performing quantitative determi-
nations of rare transcripts.
Whole PLP1 gene expression was analysed using two different
portions of the PLP/DM20 cDNA as target (Fig. 1) and two different
reference genes. While GAPDH is a widely used reference gene, the
GUSB gene has a lower expression level than GAPDH, more similar
to the levels of the PLP1-related transcripts.
Results of the two parallel real-time PCR determinations were
sufﬁciently comparable to conﬁrm the robustness of the experimental
design and the reliability of the two reference genes used. The
obtained data show a certain degree of variability, which might reﬂect
different levels of expression among patients and controls, or be due
to cell culturing, or be intrinsic to the used experimental proﬁle.
Despite this variability, the 4–5 fold increase of the PLP1 gene
expression in patients versus controls is evident. It is not clear why a
more than two-fold overexpressionwas detected. A sort of synergistic
effect between the two gene copies may be hypothesized. Or again,
the wide overexpression detected may be in part due to the cell
culturing or to the used experimental system.
To evaluate the contribution of the PLP and DM20 isoforms to PLP1
gene expressionwe directly quantiﬁed the expression of DM20, which
is the prevalent transcript isoform in ﬁbroblasts, and indirectly we
deduced the expression of PLP.
DM20 expression levels showed an only two-fold increase in
patients compared to controls. These ﬁndings were suggestive of a
possible more signiﬁcant contribution of PLP than of DM20 to
overexpression.
Quantiﬁcation of the DM20 expression level normalized to the
total PLP1 expression level conﬁrmed this indication showing a
decrease of the DM20/(DM20+PLP) ratio in patients compared to
controls.
To assign values to the DM20/(DM20+PLP) ratio in patients and
controls, the DM20 expression normalized to the total PLP1
expression was estimated using a plasmid containing the DM20
cDNA as standard. Mean DM20/(DM20+PLP) ratios resulted 0.7 in
PMD patients and 1.0 in controls, thus conﬁrming that ﬁbroblasts
from patients show a shifting of the splicing ratio in direction of thePLP isoform, besides the expected increased expression of the PLP1
gene.
Alterations of the PLP/DM20 splicing ratio have been reported, in
each case due to speciﬁc mutations lying in exon 3b (the portion of
exon 3 spliced in DM20 and not in PLP) or in intron 3 [15,19–21]. By
studying these mutations an intronic splicing enhancer (ISE) [19] and
two exonic splicing enhancers (ESE) [20,21] involved in the PLP/
DM20 splicing have been described. Overexpression of ASF/SF2 [20]
and reduction in the hnRNPH/F expression [21] have been reported as
correlating with PLP 5′ splice selection in oligodendrocytes. These
RNA-binding factors and enhancers seem to be part of a complex
splicing machinery regulating the PLP/DM20 splicing pattern. We can
speculate that the PLP1 gene expression level is one of the factors able
to inﬂuence this splicing machinery in a dose-dependent manner. In
view of this, the PLP1 gene overexpression observed in ﬁbroblasts
from duplicated patients could be the cause of the PLP/DM20 balance
alteration observed with respect to normal controls. Broadly speaking,
the level of PLP1 gene expression could drive the PLP/DM20 splice
selection being responsible, at least in part, for the different PLP/
DM20 ratios observed in different cell types and in different
developmental stages.Acknowledgements
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